ZFIN ID: ZDB-FISH-150901-20495
Fish name: s892Tg; s949Tg
Genotype: s892Tg; s949Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s892Tg; s949Tg
No data available
GENE EXPRESSION
Gene expression in s892Tg; s949Tg
RNA expression No data available
Protein expression No data available
PHENOTYPE
Phenotype in s892Tg; s949Tg
Phenotype Conditions Figures
G protein-coupled adenosine receptor activity increased occurrence, abnormal chemical treatment: pharmaceutical, chemical treatment: inhibitor Fig. 2 with image from Andersson et al., 2012
G protein-coupled adenosine receptor activity increased occurrence, abnormal chemical treatment: drug Fig. 2 with image from Andersson et al., 2012
G protein-coupled adenosine receptor activity increased occurrence, abnormal chemical treatment: pharmaceutical, chemical treatment: N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Fig. 2 with image from Andersson et al., 2012
pancreas has fewer parts of type pancreatic B cell, abnormal chemical treatment: pharmaceutical Fig. 1 with imageFig. 2 with image from Andersson et al., 2012
pancreas has normal numbers of parts of type pancreatic B cell, normal chemical treatment: pharmaceutical, chemical treatment: N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Fig. 2 with image from Andersson et al., 2012
pancreas has normal numbers of parts of type pancreatic B cell, normal chemical treatment: drug Fig. 1 with imageFig. 2 with image from Andersson et al., 2012
pancreas has normal numbers of parts of type pancreatic B cell, normal chemical treatment: pharmaceutical, chemical treatment: inhibitor Fig. 2 with image from Andersson et al., 2012
pancreas tissue regeneration increased process quality, abnormal chemical treatment: drug Fig. 2 with image from Andersson et al., 2012
pancreas tissue regeneration increased process quality, abnormal chemical treatment: pharmaceutical, chemical treatment: N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Fig. 2 with image from Andersson et al., 2012
pancreas tissue regeneration increased process quality, abnormal chemical treatment: pharmaceutical, chemical treatment: inhibitor Fig. 2 with image from Andersson et al., 2012
pancreatic B cell decreased amount, abnormal chemical treatment: metronidazole Fig. 3 with image from El Ouaamari et al., 2016
pancreatic B cell regeneration increased process quality, abnormal chemical ablation: insulin secreting cell, chemical treatment: all-trans-retinoic acid, chemical treatment: metronidazole Fig. 4 with image from Tsuji et al., 2014
pancreatic B cell regeneration increased process quality, abnormal chemical ablation: insulin secreting cell, chemical treatment: prednisolone, chemical treatment: metronidazole Fig. 4 with image from Tsuji et al., 2014

CITATIONS  (6)